Madrid (Spain), 12 May (LaPresse) – The European Medicines Agency (EMA) has reported that it is ‘actively monitoring’ the current Hantavirus outbreak linked to the cruise ship MV Hondius, in coordination with other EU bodies. ‘The EMA, through its Emergency Task Force (ETF), is ready to support the development and regulatory assessment of vaccines and therapies for Hantaviruses,’ the agency said in a statement, adding that it had ‘identified manufacturers of medicines, in particular antivirals, monoclonal antibodies and vaccines against Hantaviruses’. ‘The identification of repurposed immunomodulators for treatment and repurposed antivirals for post-exposure prophylaxis is a priority to reduce morbidity and mortality among those currently affected,’ the EMA emphasised.
Hantavirus, EMA: ‘Ready to support the development of vaccines and treatments’
Madrid (Spain), 12 May (LaPresse) – The European Medicines Agency (EMA) has reported that it is ‘actively monitoring’ the current Hantavirus outbreak linked to the cruise ship MV Hondius, in coordination with other EU bodies. ‘The EMA, through its Emergency Task Force (ETF), is ready to support the development and regulatory assessment of vaccines and therapies for Hantaviruses,’ the agency said in a statement, adding that it had ‘identified manufacturers of medicines, in particular antivirals, monoclonal antibodies and vaccines against Hantaviruses’. ‘The identification of repurposed immunomodulators for treatment and repurposed antivirals for post-exposure prophylaxis is a priority to reduce morbidity and mortality among those currently affected,’ the EMA emphasised.
